Brief Description
Inapill is developing novel therapeutics that tune immune cell metabolism (immunometabolism) to treat diseases caused by immune system overactivation and excessive inflammation.
The company was co-founded by Greg Timblin and Josh Farahzad. CEO Timblin earned his Ph.D. in Molecular & Cell Biology from UC Berkeley in 2014, in the labs of Professors Mark Schlissel and Robert Tjian. He also served as a postdoctoral fellow in Professor Kaoru Saijo’s lab at UC Berkeley, and then in Professor Val Weaver’s lab at UCSF.
Timeline
- 2023. Company founded; tenant at Bakar Labs, in the UC Berkeley Bakar BioEnginuity Hub
Inventors
Kaoru Saijo, Greg Timblin